Cargando…
Founder mutation in the PMM2 promotor causes hyperinsulinemic hypoglycaemia/polycystic kidney disease (HIPKD)
BACKGROUND: Polycystic kidney disease with hyperinsulinaemic hypoglycaemia (HIPKD) is a recently described disease caused by a single nucleotide variant, c.‐167G>T, in the promoter region of PMM2 (encoding phosphomannomutase 2), either in homozygosity or compound heterozygosity with a pathogenic...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683636/ https://www.ncbi.nlm.nih.gov/pubmed/33811480 http://dx.doi.org/10.1002/mgg3.1674 |
_version_ | 1784617459018366976 |
---|---|
author | Islam, Sumaya Tekman, Mehmet Flanagan, Sarah E. Guay‐Woodford, Lisa Hussain, Khalid Ellard, Sian Kleta, Robert Bockenhauer, Detlef Stanescu, Horia Iancu, Daniela |
author_facet | Islam, Sumaya Tekman, Mehmet Flanagan, Sarah E. Guay‐Woodford, Lisa Hussain, Khalid Ellard, Sian Kleta, Robert Bockenhauer, Detlef Stanescu, Horia Iancu, Daniela |
author_sort | Islam, Sumaya |
collection | PubMed |
description | BACKGROUND: Polycystic kidney disease with hyperinsulinaemic hypoglycaemia (HIPKD) is a recently described disease caused by a single nucleotide variant, c.‐167G>T, in the promoter region of PMM2 (encoding phosphomannomutase 2), either in homozygosity or compound heterozygosity with a pathogenic coding variant in trans. All patients identified so far are of European descent, suggesting a possible founder effect. METHODS: We generated high density genotyping data from 11 patients from seven unrelated families, and used this information to identify a common haplotype that included the promoter variant. We estimated the age of the promoter mutation with DMLE+ software, using demographic parameters corresponding to the European population. RESULTS: All patients shared a 0.312 Mb haplotype which was absent in 503 European controls available in the 1000 Genomes Project. The age of this mutation was estimated as 105–110 generations, indicating its occurrence around 600 BC, a time of intense migration, which might explain the presence of the same mutations in Europeans around the globe. CONCLUSION: The shared unique haplotype among seemingly unrelated patients is consistent with a founder effect in Europeans. |
format | Online Article Text |
id | pubmed-8683636 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86836362021-12-30 Founder mutation in the PMM2 promotor causes hyperinsulinemic hypoglycaemia/polycystic kidney disease (HIPKD) Islam, Sumaya Tekman, Mehmet Flanagan, Sarah E. Guay‐Woodford, Lisa Hussain, Khalid Ellard, Sian Kleta, Robert Bockenhauer, Detlef Stanescu, Horia Iancu, Daniela Mol Genet Genomic Med Original Articles BACKGROUND: Polycystic kidney disease with hyperinsulinaemic hypoglycaemia (HIPKD) is a recently described disease caused by a single nucleotide variant, c.‐167G>T, in the promoter region of PMM2 (encoding phosphomannomutase 2), either in homozygosity or compound heterozygosity with a pathogenic coding variant in trans. All patients identified so far are of European descent, suggesting a possible founder effect. METHODS: We generated high density genotyping data from 11 patients from seven unrelated families, and used this information to identify a common haplotype that included the promoter variant. We estimated the age of the promoter mutation with DMLE+ software, using demographic parameters corresponding to the European population. RESULTS: All patients shared a 0.312 Mb haplotype which was absent in 503 European controls available in the 1000 Genomes Project. The age of this mutation was estimated as 105–110 generations, indicating its occurrence around 600 BC, a time of intense migration, which might explain the presence of the same mutations in Europeans around the globe. CONCLUSION: The shared unique haplotype among seemingly unrelated patients is consistent with a founder effect in Europeans. John Wiley and Sons Inc. 2021-04-03 /pmc/articles/PMC8683636/ /pubmed/33811480 http://dx.doi.org/10.1002/mgg3.1674 Text en © 2021 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Islam, Sumaya Tekman, Mehmet Flanagan, Sarah E. Guay‐Woodford, Lisa Hussain, Khalid Ellard, Sian Kleta, Robert Bockenhauer, Detlef Stanescu, Horia Iancu, Daniela Founder mutation in the PMM2 promotor causes hyperinsulinemic hypoglycaemia/polycystic kidney disease (HIPKD) |
title | Founder mutation in the PMM2 promotor causes hyperinsulinemic hypoglycaemia/polycystic kidney disease (HIPKD) |
title_full | Founder mutation in the PMM2 promotor causes hyperinsulinemic hypoglycaemia/polycystic kidney disease (HIPKD) |
title_fullStr | Founder mutation in the PMM2 promotor causes hyperinsulinemic hypoglycaemia/polycystic kidney disease (HIPKD) |
title_full_unstemmed | Founder mutation in the PMM2 promotor causes hyperinsulinemic hypoglycaemia/polycystic kidney disease (HIPKD) |
title_short | Founder mutation in the PMM2 promotor causes hyperinsulinemic hypoglycaemia/polycystic kidney disease (HIPKD) |
title_sort | founder mutation in the pmm2 promotor causes hyperinsulinemic hypoglycaemia/polycystic kidney disease (hipkd) |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683636/ https://www.ncbi.nlm.nih.gov/pubmed/33811480 http://dx.doi.org/10.1002/mgg3.1674 |
work_keys_str_mv | AT islamsumaya foundermutationinthepmm2promotorcauseshyperinsulinemichypoglycaemiapolycystickidneydiseasehipkd AT tekmanmehmet foundermutationinthepmm2promotorcauseshyperinsulinemichypoglycaemiapolycystickidneydiseasehipkd AT flanagansarahe foundermutationinthepmm2promotorcauseshyperinsulinemichypoglycaemiapolycystickidneydiseasehipkd AT guaywoodfordlisa foundermutationinthepmm2promotorcauseshyperinsulinemichypoglycaemiapolycystickidneydiseasehipkd AT hussainkhalid foundermutationinthepmm2promotorcauseshyperinsulinemichypoglycaemiapolycystickidneydiseasehipkd AT ellardsian foundermutationinthepmm2promotorcauseshyperinsulinemichypoglycaemiapolycystickidneydiseasehipkd AT kletarobert foundermutationinthepmm2promotorcauseshyperinsulinemichypoglycaemiapolycystickidneydiseasehipkd AT bockenhauerdetlef foundermutationinthepmm2promotorcauseshyperinsulinemichypoglycaemiapolycystickidneydiseasehipkd AT stanescuhoria foundermutationinthepmm2promotorcauseshyperinsulinemichypoglycaemiapolycystickidneydiseasehipkd AT iancudaniela foundermutationinthepmm2promotorcauseshyperinsulinemichypoglycaemiapolycystickidneydiseasehipkd |